Objective:

To develop a 19-marker spectral flow cytometry panel for simultaneous identification of hematopoietic populations in murine bone marrow, enhancing understanding of disease mechanisms.

Approach:

Key Findings:

• The panel accurately detected long-term and short-term HSCs, multipotent progenitors, and all erythroid maturation stages, highlighting its utility in diverse research contexts.
• It consolidated three conventional panels into one, minimizing sample consumption and enhancing experimental efficiency.
• The approach successfully identified hematopoietic abnormalities in aged and β-thalassemia mouse models, underscoring its relevance in pathological studies.

Interpretation:

The developed panel provides a comprehensive and integrated view of hematopoiesis, facilitating the study of disease mechanisms and enabling targeted therapeutic interventions.

Limitations:

• The study is limited to murine models and may not directly translate to human hematopoiesis; future studies should explore cross-species applicability.
• Further validation in diverse pathological conditions is needed to enhance the robustness of the findings.

Conclusion:

This spectral flow cytometry panel is a robust tool for both basic research and translational studies, enabling comprehensive mapping of hematopoietic differentiation and informing future therapeutic strategies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.